What happened in the clinical evaluation?
Clinical Experiences With R1 And R2 for Prophylaxis Of Radiation Dermatitis In Cancer Patients
Acute radiation dermatitis (ARD) occurs in nearly 95 % of all patients receiving radiation therapy in the head and neck area. Currently, there are no evidence-based regimens for prophylaxis of radiation dermatitis or any standardised treatment recommendations. “R1 and R2” is a novel lactokine-based Class I Medical Device consisting of R1, a water-based gel which offers intense hydration to the skin while providing cooling relief and protecting skin against irritation, and R2, a soothing and moisturising lotion which has UVB and UVA protection.
Our case series reveals that the application of R1 and R2 is feasible, safe and effective for prophylaxis and for treatment of acute radiation dermatitis. Patients do much better during radiation. They have a better quality of life.
Attached are further studies into the effectiveness of R1 & R2 as a treatment for skin during and after radiotherapy treatment. The documents are in PDF format.
Spanish Published Clinical Trial
[June 2015 (148 KB – English)
South Florida Radiation Oncology Hospital Review
[Nov 2012] (148 KB – English)
First clinical Experiences – Heidelberg University Hospital, Germany
[June 2011] (361 KB – English)
University Hospital Heidelberg Germany
[June 2011] (88 KB – English)
Oslo University Hospital, Norway
[June 2011] (392 KB – English)
Fakultni Nemocnice Ostrava, Czech Republic
[May 31st, 2010] (148 KB – English)
1. DoH, 2011. Best Practice Guidance on joint working between the NHS and pharmaceutical industry and other commercial organisations. [online] Available at http://www.dh.gov.uk/en/
2: Manas, A et al. Topical R1 and R2 Prophylactic Treatment of Acute Radiation Dermatitis in Squamous Cell Carcinoma of the Head and Neck and Breast Cancer Patients Treated with Chemoradiotherapy. ePlasty 2015; 15: 211-221
If you have experienced any side effects on this product, report it to email@example.com or +27 11 372 5051